HEPION PHARMACEUTICALS, INC. Current State and Local Tax Expense (Benefit)
HEPION PHARMACEUTICALS, INC. (HEPA) reported Current State and Local Tax Expense (Benefit) of $2.97 billion for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2026-03-12
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for the quarter ending 2024-12-31 was $2.97B.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for the quarter ending 2024-09-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for the quarter ending 2024-06-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for the quarter ending 2024-03-31 was -$3.00M.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2024 was $2.97B.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2019 was -$11.40M.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2017 was $1.60M, a 15.79% decline from fiscal 2016.
- HEPION PHARMACEUTICALS, INC. current state and local tax expense (benefit) for fiscal 2016 was $1.90M.
| Period end | Current State and Local Tax Expense (Benefit) 3 month | Current State and Local Tax Expense (Benefit) 6 month | Current State and Local Tax Expense (Benefit) 6 month as first filed | Current State and Local Tax Expense (Benefit) 9 month | Current State and Local Tax Expense (Benefit) 12 month | Current State and Local Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $2.97B derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.97B derived: sum of 2 quarters · filed 2026-03-12 | $2.97B derived: sum of 3 quarters · filed 2026-03-12 | $2.97B 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | -$3.00M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.00M 10-Q · filed 2025-08-14 | $3.00M 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | -$3.00M 10-Q · filed 2025-05-19 | |||||
| 2019-12-31 | -$11.40M 10-K · filed 2021-03-31 | |||||
| 2017-06-30 | $1.60M 10-KT · filed 2018-03-26 | $1.90M 10-K · filed 2017-09-28 | ||||
| 2016-06-30 | $1.90M 10-KT · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |